Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects

British Journal of Nutrition

Volumn 95, Issue 5, 2006, Pages 968-975

  Greyling, A ^a   De Witt, C ^a   Oosthuizen, W ^a   Jerling, J C ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Cholesterol; Familial hypercholesterolaemia; Lipids; Policosanol

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTA 60; PLACEBO; POLICOSANOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EDEMA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEADACHE; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

SACCHARUM;

EID: 33744458949     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1079/BJN20061715     Document Type: Article

References (63)

1. Aleman CL, Mas R, Hernandez C, Rodeiro I, Cerejido E, Noa M, Capote A, Menendez R, Amor A & Fraga V (1994) A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 70, 77-87.
2. Aleman CL, Puig MN, Elias EC, Ortega CH, Guerra IR, Ferreiro RM & Brinis F (1995) Carcinogenicity of policosanol in mice: an 18-month study. Food Chem Toxicol 33, 573-578.
3. Aneiros E, Mas R, Calderon B, Illnait J, Fernandez L, Castano G & Fernandez JC (1995) Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res 56, 176-182.
4. Arruzazabala ML, Carbajal D, Mas R, Molina V, Valdes S & Laguna A (1994) Cholesterol-lowering effects of policosanol in rabbits. Biol Res 27, 205-208.
5. Batista J, Stusser R, Saez F & Perez B (1996) Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 34, 134-137.
6. Benitez M, Romero C, Mas R, Fernandez L & Fernandez JC (1997) A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res 58, 859-867.
7. Canetti MM, Moreira M, Mas R, Illnait J, Fernandez L & Fernandez JC (1997) Effects of policosanol on primary hypercholesterolemia: a 3-year open-extension follow-up. Curr Ther Res 58, 868-875.
8. Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E & Castano G (1995) A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 15, 159-165.
9. Castano G, Canetti M, Moreira M, Tula L, Mas R, Illnait J, Fernandez L, Fernandez JC & Diaz E (1995a) Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr Ther Res 56, 819-828.
10. Castano G, Fernandez L, Mas R, Illnait J, Fernandez J, Mesa M, Alvarez E & Lezcay M (2002a) Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 22, 55-66.
11. Castano G, Fernandez L, Mas R, Illnait J, Mesa M & Fernandez JC (2003a) Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Invest 23, 639-650.
12. Castano G, Mas R, Arruzazabala ML, Noa M, Illnait J, Fernandez JC, Molina V & Menendez A (1999a) Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 19, 105-116.
13. Castano G, Mas R, Cesar Fernandez J, Pontigas V, Suazo M & Fernandez L (1998) Open-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 59, 737-745.
14. Castano G, Mas R, Fernandez JC, Fernandez L, Alvarez E & Lezcay M (2000a) Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Ther Res 61, 137-146.
15. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J & Lopez E (2002b) Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs RD 3, 159-172.
16. Castano G, Mas R, Fernandez L, Fernandez JC, Illnait J, Lopez LE & Alvarez E (2000b) Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 14, 187-195.
17. Castano G, Mas R, Fernandez JC & Illnait J (1997) Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Curr Ther Res 58, 154-162.
18. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L & Alvarez E (2001a) Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 56, M186-M192.
19. Castano G, Mas R, Fernandez L, Illnait J, Gamez R & Alvarez E (2001b) Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 21, 43-57.
20. Castano G, Mas R, Fernandez L, Illnait J, Gamez R & Fernandez JC (2001c) Comparison of two regimens of policosanol administered at 20 mg /d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Curr Ther Res 62, 194-208.
21. Castano G, Mas R, Fernandez L, Illnait J, Hernandez E, Fernandez JC, Gamez R, Gutierrez C & Alvarez E (2002c) A randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia. Curr Ther Res 63, 286-303.
22. Castano G, Mas R, Fernandez L, Illnait J, Mesa M, Alvarez E & Lezcay M (2003b) Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20, 153-163.
23. Castano G, Mas R, Fernandez JC, Lopez LE & Fernandez L (1999b) A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 60, 379-391.
24. Castano G, Mas R, Fernandez J, Lopez E, Illnait J, Fernandez L & Mesa M (2003c) Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study. Curr Ther Res 64, 522-537.
25. Castano G, Mas R, Nodarse M, Illnait J, Fernandez L & Fernandez JC (1995b) One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res 56, 296-304.
26. Castano G, Menendez R, Mas R, Amor A, Fernandez JL, Gonzalez RL, Lescay M & Alvarez E (2002d) Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 22, 89-99.
27. Castano G, Tula L, Canetti M, Morera M, Mas R, Illnait J, Fernandez L & Fernandez JC (1996) Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res 57, 691-699.
28. Civeira F. (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68.
29. Crespo N, Alvarez R, Mas R, Illnait J, Fernandez L & Fernandez JC (1997) Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res 58, 44-51.
30. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J & Castano G (1999) Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non-insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 19, 117-127.
31. Fernandez JC, Mas R, Castano G, Menendez R, Amor AM, Gonzalez RM & Alvarez E (2001) Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Investig 21, 103-113.
32. Fernandez L, Mas R, Illnait J & Fernandez JC (1998) Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res 59, 717-722.
33. Friedewald WT, Levy RI & Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.
34. Gamez R, Aleman CL, Mas R, Noa M, Rodeiro I, Garcia H, Hernandez C, Menendez R & Aguilar C (2001) A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. J Med Food 4, 57-65.
35. Gouni-Berthold I & Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143, 356-365.
36. Hargrove JL, Greenspan P & Hartle DK (2004) Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med (Maywood) 229, 215-226.
37. Janikula M (2002) Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 7, 203-217.
38. Lin Y, Rudrum M, van der Wielen RP, Trautwein EA, McNeill G, Sierksma A & Meijer GW (2004) Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 53, 1309-1314.
39. McNamara DJ (1994) Cardiovascular disease. In: Modern nutrition in health and disease, pp. 1533-1544 [ME Shils, JA Olson and M Shike, editors]. Philodelphia: Lea and Febiger.
40. Marcello S, Gladstein J, Tesone P & Mas R (2000) Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: a pilot study. Curr Ther Res 61, 346-357.
41. Margetts B & Nelson M (1997) Design Concepts in Nutritional Epidemiology, 2nd edn. Oxford: Oxford University Press.
42. Mas R (2000) Policosanol. Hypolipidemic antioxidant treatment of atherosclerosis. Drugs Future 25, 569-586.
43. Mas R, Castano G, Fernandez L, Illnait J, Fernandez J & Alvarez E (2001) Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest 21, 485-497.
44. Mas R, Castano G, Illnait J, Fernandez L, Fernandez J, Aleman C, Pontigas V & Lescay M (1999a) Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 65, 439-447.
45. Mas R, Rivas P, Izquierdo JE, Hernandez R, Fernandez L, Fernandez J, Orta SD, Illnait J & Ricardo Y (1999b) Pharmacoepidemiologic study of policosanol. Curr Ther Res 60, 458-467.
46. Menendez R, Amor AM, Gonzalez RM, Fraga V & Mas R (1996) Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 29, 253-257.
47. Menendez R, Amor AM, Rodeiro I, Gonzalez RM, Gonzalez PC, Alfonso JL & Mas R (2001) Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 32, 8-12.
48. Menendez R, Arruzazabala L, Mas R, et al. (1997) Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 77, 923-932.
49. Menendez R, Fernandez SI, Del Rio A, Gonzalez RM, Fraga V, Amor AM & Mas RM (1994) Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 27, 199-203.
50. Mirkin A, Mas R, Martinto M, Boccanera R, et al. (2001) Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res. 21, 31-41.
51. Murphy KJ, Saint DA & Howe PR (2004) Lack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 13, S69.
52. Ortensi G, Julio G, Hector V & Pedro AT (1997) A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 58, 390-401.
53. Pappu AS & Illingworth DR (2002) The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 165, 137-144.
54. Pons P, Illnait J, Mas R, Rodriguez M, Aleman C, Cesar Fernandez J, Fernandez L & Martin M (1997) A comparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res 58, 26-35.
55. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L & Fernandez JC (1994) Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 14, 27-33.
56. Rodriguez MD & Garcia H (1994) Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 14, 107-113.
57. Rodriguez MD & Garcia H (1998) Evaluation of peri- and post-natal toxicity of Policosanol in rats. Teratog Carcinog Mutagen 18, 1-7.
58. Rodriguez-Echenique C, Mesa R, Mas R, Noa M, Menendez R, Gonzalez RM, Amor AM, Fraga V, Sotolongo V & Laguna A (1994) Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 32, 565-575.
59. Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ & Kastelein JJ (2003) Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 253, 161-168.
60. Siavoshian S, Simoneau C, Maugeais P, Marks L, Rodary L, Gardette J & Krempf M (1995) Measurement of mevalonic acid in human urine by bench top gas chromatography-mass spectrometry. Clin Chim Acta 243, 129-136.
61. Torres O, Agramonte AJ, Illnait J, Mas Ferreiro R, Fernandez L & Fernandez JC (1995) Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18, 393-397.
62. Varady KA, Wang Y & Jones PJH (2003) Role of policosanols in the prevention and treatment of cardiovascular disease. Nutr Rev. 61, 376-383.
63. Wang YW, Jones PJH, Pischel I & Fairow C (2003) Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 38, 165-170.